Related Experiment Video

Updated: Jul 11, 2026

An Orthotopic Bladder Cancer Model for Gene Delivery Studies
07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

Emerging drugs for targeted therapy of bladder cancer

Piyush K Agarwal1, Peter C Black, David J McConkey

  • 1Department of Urology, University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA.

Expert Opinion on Emerging Drugs
|September 19, 2007
PubMed

Insights

New targeted therapies show promise for bladder cancer treatment by inhibiting overexpressed tyrosine kinase growth factor receptors. These novel small-molecule drugs offer a potential advancement over current organ-confined disease management strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Current treatments for organ-confined bladder cancer rely on surgery and surveillance.
  • Chemotherapy is effective for metastatic disease, but targeted therapies are needed.
  • Overexpression of receptor tyrosine kinases drives cancer cell proliferation and survival.

Purpose of the Study:

  • To review the potential of targeted small-molecule therapies for bladder cancer.
  • To discuss the role of receptor tyrosine kinases in bladder cancer development.
  • To evaluate novel targeted drugs, including tyrosine kinase inhibitors and monoclonal antibodies.

Main Methods:

  • Review of existing studies on targeted therapies in various malignancies.
  • Analysis of the role of receptor tyrosine kinases in cancer cell growth.
  • Discussion of the application of targeted drugs in bladder cancer models.

Main Results:

  • Receptor tyrosine kinases are implicated in cancer proliferation and antiapoptotic pathways.
  • Targeted small-molecule therapies have demonstrated efficacy in preclinical tumor models.
  • Novel targeted drugs offer a promising avenue for bladder cancer treatment.

Conclusions:

  • Targeted therapies directed at receptor tyrosine kinases represent a significant advancement.
  • These novel agents hold potential for improved treatment of bladder cancer.
  • Further research into tyrosine kinase inhibitors and monoclonal antibodies is warranted for bladder cancer therapy.

More Related Videos

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...